Clovis enters research collaboration with Irish biopharmaceutical firm
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has entered into a research agreement with Alkermes plc, a biopharmaceutical company based in Dublin.
The collaboration will evaluate ALKS 4230, an immunotherapy developed by Alkermes, in combination with rucaparib and lucitanib, two inhibitors developed by Clovis.
The research will explore the potential anti-cancer effects of both treatment combinations in multiple tumor types. The research could form the basis of potential future clinical studies of the combinations.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has entered into a research agreement with Alkermes plc, a biopharmaceutical company based in Dublin.
The collaboration will evaluate ALKS 4230, an immunotherapy developed by Alkermes, in combination with rucaparib and lucitanib, two inhibitors developed by Clovis.
The research will explore the potential anti-cancer effects of both treatment combinations in multiple tumor types. The research could form the basis of potential future clinical studies of the combinations.
…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
